Predicting brain metastasis risk in hormone positive breast cancer
Part of Cancer, Skin clinical trials.
This study tests a model that predicts the risk of breast cancer spreading to the brain. It looks at women with hormone receptor positive breast cancer to help doctors better identify who might need closer monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that is hormone receptor (HR) positive.
- You must not have had brain metastases at diagnosis or within the first 3 months after diagnosis.
- You must not have cancer in both breasts (bilateral breast cancer).
- You must not have another type of cancer diagnosed at the same time (like lung cancer or melanoma).
- Your doctor must have complete medical information about your cancer at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at whether routine brain scans (MRI) at the time of diagnosis of metastatic breast cancer can help detect brain metastases early, even before they cause symptoms. It aims to understand how common brain metastases are in high-risk breast cancer and whether early detection can help guide treatment decisions. This may be relevant for people with certain types of breast cancer that have spread to other organs.
This study looks at what factors affect how long people with breast cancer that has spread to the brain live. It uses past medical records to find patterns that may help plan better care.
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
This study is testing regular MRI brain scans to find any brain metastases early in people with HER2-positive breast cancer that has spread. It aims to see if early detection can help guide treatment and improve outcomes.
This trial uses an MRI scan to look for early signs of breast cancer spreading to the brain in people with certain aggressive breast cancer types (triple-negative or HER2-positive) that are stage IIb or III. The goal is to find and treat brain metastases earlier, before they cause symptoms.
This trial tests whether regular brain MRI scans can help detect brain metastases early in patients with stage IV breast cancer who do not yet have any known brain metastases. The goal is to see if early detection improves outcomes.
Hear when a new Breast Cancer, Estrogen Receptor-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.